Grünenthal Pharma develops a digital platform to support training in pain physicians in AP

-the objective of this platform is to maintain the highest standards of scientific content, educational quality and interactivity with the user

– allows access multichannel from the most advanced devices on the market: Ipad ®, Iphone ®, Blackberry or Smartphone

-the first didactic material is an interactive online tutorial containing information about a transdermal patch of buprenorphine indicated for the relief of chronic pain of moderate to severo1

Madrid September 2011.- Grünenthal Pharma, leading pharmaceutical company in the treatment of painIt launches a platform aimed at physicians for primary care which aims to expand its training and information in the field of analgesia. This space, which can be accessed through www.gru-learning.com, is first content a tutorial on a transdermal patch analgesic indicated for the relief of the pain of moderate to severo1. Subsequently, new items will be added and you will remain informed the collective doctor about these updates.

According to data provided by the Pain Proposal Patient Survey, one in five European adults have pain crónico2, 3, by which becomes increasingly important support these health professionals training in chronic pain, using the new technologies available.

Centralization of content

The multi-channel platform allows host and centralise different contents of e-detailing as: clinical studies, documents, presentations, Bank of images, bibliographic alerts and various publications. This unification of materials will help to turn it into a meeting point for professionals. As a result, the purpose of this platform is to maintain the highest standards of scientific content, educational quality and interactivity with the user.

Access is through an area of registration of participants. Once identified, the user can share information and keep in touch through e-detailing.

About Grünenthal

Grünenthal group is a pharmaceutical company international, independent and family-owned based on research and headquartered in Aachen, Germany. Taking advantage of its position in the area of the treatment of pain, its aim is to become more patient-centred company in order to be a leader in therapeutic innovation. In total, the Grünenthal group has subsidiaries in 36 countries around the world. Grünenthal products are sold in over 100 countries and work approximately 4,900 employees the Grünenthal group around the world, of which 512 was found in the region of Iberia. In 2010, Grünenthal reached a turnover of 910 M €.

On the other hand, Grünenthal Pharma, the Spanish subsidiary of the Grünenthal group, ranked 17 in the Group of companies of between 250 and 500 employees in the prestigious ranking ‘ Best WorkPlaces 2011 Spain ’, produced by Great Place to Work ®